Asset profile
ONO-1110
Small molecule
Evidence outlook · lead readout
NCT06792136 · Major Depressive Disorder (MDD
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06792136: The trial randomized 103 participants to ONO-1110 or placebo and masked both participants and investigators. Its primary endpoint was change in the clinical HAM-D17 depression score at Week 8, but results are not posted, so whether the primary endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.